List of Excipients in Branded Drug ROFLUMILAST

Generic Drugs Containing ROFLUMILAST

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	roflumilast	0378-1905	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	roflumilast	0378-1905	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	roflumilast	0378-1905	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in ROFLUMILAST?

# Of NDCs	Excipient
1	CARBOXYMETHYLCELLULOSE CALCIUM
3	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31

Roflumilast Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Roflumilast has two distinct formulation businesses: low-dose oral tablets for chronic obstructive pulmonary disease and topical products for plaque psoriasis and atopic dermatitis. The strongest commercial opportunity is topical delivery, where excipient selection affects solubility, skin penetration, tolerability, cosmetic acceptability, container compatibility, and patent differentiation.

The oral product is a mature, low-dose generic opportunity. The topical products retain greater value because their formulation, vehicle, dosage form, and method-of-use claims can create barriers beyond the roflumilast molecule itself.

What approved roflumilast products use excipients?

Roflumilast is marketed in the United States as Daliresp tablets and Zoryve cream and foam. The approved topical products use different vehicles for different disease sites and patient populations.

Product	Roflumilast strength	Dosage form	FDA indication	Primary formulation objective
Daliresp	500 mcg	Immediate-release tablet	COPD maintenance treatment	Accurate low-dose oral delivery
Zoryve cream	0.3% and 0.15%	Topical cream	Plaque psoriasis and atopic dermatitis	Skin deposition with acceptable spreadability
Zoryve foam	0.3%	Topical foam	Seborrheic dermatitis	Scalp and hair-bearing-area delivery

Daliresp contains a conventional tablet excipient system including lactose monohydrate, starch, crospovidone, povidone and magnesium stearate, according to the prescribing information. The formulation challenge is dose uniformity rather than high drug loading: each tablet contains only 0.5 mg of active ingredient.

Zoryve cream uses a semisolid emulsion system with fatty alcohols, glyceryl stearate, dimethicone, isopropyl myristate, medium-chain triglycerides, polysorbate 60, propylene glycol and preservative components. The vehicle is designed to solubilize or disperse roflumilast while maintaining a spreadable, non-occlusive cream.

Zoryve foam uses a volatile, low-residue vehicle suited to the scalp and other hair-bearing areas. Its excipient system includes ethanol, diethylene glycol monoethyl ether, propylene glycol, surfactant, fatty alcohols, buffering components and water. The foam format avoids the poor cosmetic profile that can limit adherence to creams or ointments on the scalp. (Arcutis Biotherapeutics, 2024a; U.S. Food and Drug Administration, 2022)

Why does excipient selection matter for roflumilast?

Roflumilast is a potent PDE4 inhibitor administered at very low doses orally and at relatively low concentrations topically. Its formulation profile creates several excipient requirements.

Solubility and dose uniformity

The oral tablet must distribute 500 mcg of active ingredient uniformly throughout a compressed tablet. A high-performance wetting and blending system can reduce content-uniformity risk, particularly for generic manufacturers using a different granulation process.

For topical products, the formulation must maintain a consistent concentration during storage and application. Solubilizers, co-solvents and emollients can reduce crystallization risk. The selection must be balanced against skin irritation, odor, evaporation rate and regulatory acceptability.

Skin delivery

The topical commercial objective is usually local skin exposure with limited systemic exposure. Excipients can alter:

• Roflumilast solubility in the vehicle
• Partitioning into the stratum corneum
• Release from the formulation
• Residence time on skin
• Evaporation and drying
• Wash-off resistance
• Local irritation and sensitization

Diethylene glycol monoethyl ether, propylene glycol, medium-chain triglycerides, isopropyl myristate and silicone components each offer different trade-offs in penetration, feel and formulation stability. A developer seeking to design an alternative product must establish that any change does not materially alter local exposure, systemic safety or clinical performance.

Patient adherence

The commercial value of the foam is linked to usability. A vehicle that spreads through hair, dries quickly and leaves limited residue may produce better real-world adherence than a conventional cream. A cream may remain preferable for plaque psoriasis or atopic dermatitis on larger, less hair-bearing body surfaces because it can provide more sustained emolliency.

Excipient systems that improve sensory properties can support lifecycle management even when they do not produce a new active ingredient.

What formulation patents protect roflumilast products?

Roflumilast intellectual property has multiple layers:

1. The active pharmaceutical ingredient and chemical synthesis.
2. Oral dosage forms and low-dose tablet manufacturing.
3. Topical compositions.
4. Foam and aerosolized dosage forms.
5. Treatment methods for psoriasis, seborrheic dermatitis and atopic dermatitis.
6. Concentration, dosing frequency and patient-population claims.
7. Manufacturing controls, packaging and stability.

The original chemical patent estate is materially older than the topical product estate. Roflumilast received U.S. approval for COPD in 2011, while topical Zoryve products were approved much later. The commercial patent risk therefore depends heavily on whether a competitor targets the active ingredient, the dosage form, the vehicle or the indication.

The strongest formulation barriers are likely to arise from topical composition and foam technology rather than from conventional tablet excipients. A generic tablet manufacturer can often design around routine excipients. A competing topical product must address vehicle performance, product quality, clinical bridging and patent claims at the same time.

The FDA Orange Book should be reviewed for current listed patents and regulatory exclusivity associated with Daliresp and Zoryve. Patent listings can change as products receive new strengths, indications or dosage forms. Orange Book listing does not determine ultimate patent validity, but it can create an ANDA Paragraph IV litigation pathway. (U.S. Food and Drug Administration, 2024a)

When does roflumilast lose exclusivity?

Roflumilast has already lost new chemical entity exclusivity for its oral COPD product. Daliresp was approved in 2011, making the five-year NCE period expire in 2016, subject to any applicable pediatric extension or other statutory adjustment.

The topical products are different. Zoryve cream received U.S. approval in 2022 for plaque psoriasis and later expanded to atopic dermatitis. Zoryve foam received approval in 2023 for seborrheic dermatitis. These approvals generated new regulatory exclusivity periods and support separate patent strategies.

Exclusivity layer	Commercial relevance
Original NCE exclusivity	Expired for oral roflumilast
Oral product patents	May delay or complicate generic tablet entry
Topical formulation patents	Can protect cream and foam products after molecule-level exclusivity
New indication exclusivity	Can restrict approval for a specific use without blocking all roflumilast products
Pediatric exclusivity	Can add six months if granted and applicable
Orphan-drug exclusivity	Not the primary protection for current roflumilast products

The practical entry date is not determined by NCE exclusivity alone. A generic company must evaluate listed patents, Paragraph IV certifications, patent litigation, regulatory exclusivity, potential settlements and the scope of any approved label.

What generic entry risks exist for Daliresp?

The oral tablet is the clearest generic target. The active ingredient is established, the dose is small, and the dosage form is conventional. A successful ANDA applicant could compete through:

• Direct tablet substitution
• Alternative excipient systems
• Dry granulation or wet granulation
• Improved content-uniformity controls
• Lower-cost manufacturing
• Contract manufacturing for regional markets

The main technical risks are low-dose blend uniformity, dissolution equivalence, impurity control and stability. A generic developer should not assume that the simplest formulation is the lowest-risk formulation. At a 500-mcg dose, segregation and sampling error can produce meaningful batch variation.

Commercial erosion may be slower than for high-volume primary-care drugs because COPD maintenance prescribing includes payer controls, established brand relationships and potentially limited patient volume relative to major inhaled therapies. The tablet also has no device-related barrier, making substitution easier than for inhaled products.

Can generic companies substitute Zoryve cream or foam?

Topical substitution is more complex than oral tablet substitution.

A generic cream must demonstrate pharmaceutical equivalence and meet FDA requirements for topical products. Depending on the product and regulatory pathway, approval may require comparative physicochemical characterization, in vitro release testing, in vitro permeation testing, clinical endpoint studies or other comparative evidence.

The foam creates a higher barrier because performance depends on:

• Foam generation and collapse
• Droplet or globule characteristics
• Roflumilast distribution
• Spray or actuator behavior
• Propellant and container interaction
• Drying time
• Hair-bearing-area application
• Microbial and preservative control

The foam package is part of the product. A substitute using a different canister, valve, propellant or actuator may not reproduce the reference product's performance.

A competitor could avoid direct substitution by launching a 505(b)(2) product with a different vehicle, strength, indication or dosage form. That path can create a differentiated product but may require clinical data and may face method-of-use or formulation patent claims.

What excipient opportunities exist for topical roflumilast?

Preservative-reduced or preservative-free cream

A preservative-reduced system could appeal to patients with sensitive or eczematous skin. The main technical requirement is microbiological control during in-use storage. Airless packaging, single-dose packaging or a low-water system could reduce preservative demand.

This opportunity has commercial value in atopic dermatitis, where chronic use and skin-barrier impairment increase concern about tolerability.

Low-residue scalp vehicles

A foam competitor could target faster drying, reduced greasiness and improved hair compatibility. Candidate systems may include volatile solvents, silicone-based components, lower-residue emollients or alternative surfactant packages.

The product must preserve roflumilast solubility and avoid excessive evaporation that causes crystallization on the skin.

Waterless or anhydrous systems

An anhydrous gel, ointment, balm or solution could improve chemical stability and reduce microbial risk. The trade-off is cosmetic acceptability. An ointment may support barrier repair but could perform poorly on the scalp or in warm climates.

Spray and solution dosage forms

A spray could improve application to large affected areas. A solution may be suitable for scalp use, but both formats can create inhalation, ocular exposure and dose-delivery concerns. Packaging accuracy and uniform coverage would be central development issues.

Pediatric-friendly formulations

Lower-strength roflumilast cream, including the 0.15% product approved for atopic dermatitis, expands the pediatric and sensitive-skin opportunity. Excipient selection should minimize fragrance, sensitizers, unnecessary volatile components and known irritants.

The strongest commercial positioning would combine a lower-strength product with a simple, low-irritancy vehicle and packaging that supports accurate application.

How does roflumilast compare with competing topical drugs?

Product	Active ingredient	Formulation opportunity	Main competitive issue
Zoryve cream	Roflumilast	Low-strength and higher-strength cream	Indication breadth and tolerability
Zoryve foam	Roflumilast	Scalp and hair-bearing-area delivery	Foam technology and substitution difficulty
Eucrisa	Crisaborole	Ointment vehicle	Burning and tolerability complaints
Vtama	Tapinarof	Cream formulation	Nonsteroidal psoriasis positioning
Opzelura	Ruxolitinib	Cream vehicle and concentration	Safety labeling and use restrictions
Topical corticosteroids	Multiple	Broad range of creams, ointments and foams	Low cost and established prescribing

Roflumilast competes as a nonsteroidal PDE4 inhibitor with topical products that differ in mechanism, safety profile and cosmetic performance. Excipient strategy can influence the practical comparison as much as the active ingredient. A less greasy, faster-drying or lower-irritancy product may gain share without changing pharmacology.

What manufacturing and intellectual-property barriers affect commercial entry?

The principal manufacturing barriers are not unusual raw-material constraints. They are process-control and product-performance barriers.

For tablets, the key controls are API particle size, blending, granulation, content uniformity, dissolution and impurity profile.

For creams, the critical variables include:

• Emulsion droplet size
• Homogenization energy
• API particle size or dissolved state
• Viscosity
• pH
• Preservative effectiveness
• Fill-weight accuracy
• Tube or pump compatibility

For foams, the critical variables include:

• Foam density
• Expansion ratio
• Collapse time
• Valve performance
• Container pressure
• API solubility
• Temperature stability
• Delivered mass per actuation

A formulation patent can be designed around excipient concentration ranges, solvent ratios, phase composition, pH, particle-size limits, foam characteristics or stability outcomes. Such claims are more difficult to invalidate when supported by comparative data showing an unexpected improvement in solubility, skin delivery, stability or patient acceptability.

Which licensing opportunities exist around roflumilast?

Licensing opportunities are strongest in three areas.

First, regional commercialization rights could support companies with dermatology sales infrastructure but no proprietary PDE4 topical product.

Second, formulation technology licensing could apply to foam generation, airless packaging, anhydrous systems, low-irritancy emulsions or scalp delivery.

Third, generic and 505(b)(2) partnerships could combine a low-cost roflumilast supply source with a proprietary vehicle or dosage form.

The most defensible deal structure would tie royalties to product-specific formulation rights rather than to the roflumilast molecule alone. The molecule is mature, while differentiated topical delivery can support longer commercial life.

What is the regulatory status of roflumilast?

The FDA-approved products include:

• Daliresp 500 mcg tablets for reducing the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
• Zoryve 0.3% cream for plaque psoriasis.
• Zoryve 0.15% cream for mild to moderate atopic dermatitis.
• Zoryve 0.3% foam for seborrheic dermatitis.

Roflumilast is not a biologic, so biosimilar risk does not apply. Competitive risk comes from ANDA generics, 505(b)(2) products and alternative nonsteroidal topical therapies.

Key Takeaways

• Oral roflumilast is a mature low-dose tablet opportunity with conventional excipient requirements.
• The commercial value is concentrated in topical cream and foam delivery.
• Zoryve foam has a higher technical substitution barrier than Zoryve cream because the package, vehicle and foam performance are interdependent.
• Excipient innovation can target solubility, skin penetration, drying time, residue, tolerability, preservation and pediatric use.
• Preservative-reduced creams, low-residue scalp vehicles, waterless systems and accurate spray formats are credible lifecycle opportunities.
• The original oral NCE exclusivity period has expired, while topical products rely more heavily on formulation, indication and use-related protection.
• Generic tablet entry is structurally easier than direct generic substitution of topical foam.
• The strongest licensing assets are proprietary topical vehicles and delivery systems, not routine tablet excipients.

FAQs

Is roflumilast a BCS Class II drug?

Roflumilast is generally treated as a low-solubility compound for formulation development, although formal BCS classification depends on the regulatory framework and supporting data. Solubilization, particle engineering and dissolution control remain relevant development issues.

Which excipient is most important in roflumilast foam?

No single excipient determines performance. The solvent, surfactant, fatty-alcohol system, propellant or volatile phase, container and valve operate as an integrated delivery system.

Can roflumilast be formulated as an ointment?

Yes, an ointment is technically feasible, but it may have weaker cosmetic acceptance than a cream or foam. The main commercial limitations would be greasiness, scalp compatibility and patient adherence.

Is a new roflumilast cream automatically eligible for an ANDA?

No. An ANDA requires the appropriate reference product, pharmaceutical equivalence and bioequivalence evidence. A materially different vehicle, strength, indication or dosage form may require a 505(b)(2) pathway instead.

Does roflumilast have biosimilar competition?

No. Roflumilast is a small-molecule drug. The relevant competitors are generic tablets, topical generics, 505(b)(2) products and other nonsteroidal dermatology therapies.

References

1. Arcutis Biotherapeutics. (2024a). Zoryve (roflumilast) cream and foam prescribing information. U.S. Food and Drug Administration.

2. Arcutis Biotherapeutics. (2024b). Zoryve (roflumilast) cream 0.15% prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2011). Daliresp (roflumilast) tablets prescribing information.

4. U.S. Food and Drug Administration. (2022). FDA approves new treatment for plaque psoriasis. FDA.

5. U.S. Food and Drug Administration. (2023). FDA approves foam formulation of roflumilast for seborrheic dermatitis. FDA.

6. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

7. U.S. Pharmacopeia. (2024). General chapters on pharmaceutical dosage forms, topical and semisolid drug products, and microbial limits. United States Pharmacopeial Convention.